Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Trial ID or NCT#

NCT02216409

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.

Official Title

A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies

Eligibility Criteria

Ages Eligible for Study: Older than 18
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma
  2. Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.
  3. Adequate hematologic status
  4. Adequate coagulation function
  5. Adequate hepatic function
  6. Adequate renal function
Exclusion Criteria:
  1. Known primary tumors of central nervous system disease
  2. Known active brain metastases
  3. Known cardiopulmonary disease
View All Criteria
Show Less

Investigator(s)

Youn H Kim, MD
Youn H Kim, MD
Dermatologic oncologist, Cutaneous oncology specialist, Dermatologist
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Michael Khodadoust
Michael Khodadoust
Lymphoma specialist, Cutaneous oncology specialist, Hematologist, Hematologist-Oncologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Branimir I Sikic

Contact us to find out if this trial is right for you.

Contact

CCTO
1-650-498-7061

View on ClinicalTrials.gov